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Editorial: NMS, and Why We Should Call It
(Malignant) Catatonia
Robert Arnold Johnson, M.D. (PGY4)
The review in the current issue by Guzofski and Peralta, “Neuroleptic Malignant
Syndrome, with Attention to Its Occurrence with Atypical Antipsychotic
Medication: A Review,” reminds me of the influence of a name. I am thinking here
of the name, “neuroleptic malignant syndrome” (NMS), which was coined by
Delay in 1960, following reports of “catatonic-like” states resulting from
phenothiazines, and popularized through an influential review by Caroff in 1980
(1, 2).
A very similar syndrome, recognized as an advanced (excited, lethal, malignant,
pernicious) form of catatonia had been described well before the advent of the
typical antipsychotic medications. And catatonic features often are an overt feature
of NMS (3-5). In addition, simple catatonia is recognized as a risk factor for NMS
if typical neuroleptic is given (5). Even so, the name of NMS took on a life of its
own, a meme, we might say, that began to spread from one psychiatrist’s mind to
another independently of the meme(s) for catatonia, despite the efforts of some to
stem the tide (3). I offer as proof of this last sentence two first-hand observations.
First, I find that few of my peers are aware of a link between, or similarity of,
NMS and malignant catatonia (MC). Second, Doctors Guzofski and Peralta did not
include much mention of MC in their original submission. And, I suspect, nothing
unusual at all resides in either of these observations. A very large number of
psychiatrists and psychiatry residents do not realize NMS and MC are linked
concepts, that’s my guess. I have been luckier myself. Two of my mentors when I
was a PGY2 on the Consultation-Liaison rotation here at Jefferson, Dr. David
Lynn and Dr. Dimitri Markov, taught me about MC and encouraged me to dig into
its literature; as I did that, I learned about its link with NMC. And for that I have
most to thank Dr. Max Fink and his colleague, Dr. Michael Alan Taylor (6, 7).
They are not the only, or even the first, authors to speak of a link between MC and
NMS (3), but Dr. Fink, especially, has been the most declamatory on the topic, the
one most emphatic that the matter of language, the matter of the name, has a lot to
do with how we clinicians behave.
His point of view is that NMS is a variant of, or a subtype of, MC: MC that
happens to have been triggered by an antipsychotic medication. (The same is true,
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he believes, of serotonin syndrome: a subtype of MC, one that has been triggered
by serotonergic excess.) And this view has a highly practical implication, namely,
that treatment that is effective for catatonia should not be withheld from those
suffering from NMS. He is thinking of benzodiazepine (lorazepam is used most
often) and, should that medication prove ineffective within a few days,
electroconvulsive therapy (ECT). The dose of lorazepam that is required is often
quite high, so the schedule by which it is advanced will need to be aggressive
(taking care not to produce oversedation or respiratory compromise, of course); it
can be given parenterally, and should be in some instances (8).
So, having brought the memes of MC and NMS together in your mind, you
become vigorous in the application of benzodiazepine. But it is in the early use
(“early” in a relative sense) of ECT that your thinking is most changed by
comparison with your thinking had the two memes remained estranged. And that’s
because the NMS meme, as an isolated thing, does not lead to thinking of ECT (or
benzodiazepine) early on. It is modeled on another meme (by “meme”—maybe I
should be speaking of a whole family of them—I mean, of course, a word or
phrase or idea that appears to spread from mind to mind in the Dawkins sense, as a
selfish gene might, were it possible for a gene to spread from mind to mind), that
of malignant hyperthermia (MH), which brings forward first the idea of supportive
care, especially with regard to control of body temperature and fluid volume, and
this, of course, is a fine outcome even were MC and NMS two separate things.
And next among the weapons summoned up by the NMS meme(s) is the drug
dantrolene (a direct-acting muscle-relaxant that affects calcium flux from the
endoplasmic reticulum), also bromocriptine (a dopamine agonist to fix the
hypodopominergic state that the neuroleptic caused), amantadine (another
dopaminergic drug), or both. And uncontrolled but careful clinical studies provide
good support for the use of dantrolene and dopaminergic drugs in NMS (1, 5). It’s
not that their use is to be avoided, it’s that ECT should not be put off long if they,
as adjuncts to benzodiazepine, have not relieved the disorder within a few days.
And Dr. Fink’s point is this: ECT is likely to be put off too long if the concepts of
NMS and MC are not linked in the clinician’s mind, brought together in the one
idea that the former is a special subtype of the latter. Two excellent books on
catatonia, both published recently, support this opinion and document its history
(9, 10).
No randomized studies of ECT in MC or NMS exist, but clinical experience with
its good effectiveness in these conditions, which I, following Fink and several
others, shall link together as one, is fairly extensive (1, 2, 5, 6, 11-14). It appears to
be safe generally, but at least two patients have died as a consequence, so some
caveats are in order. First is that neuroleptic must be stopped as far in advance of
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the procedure as possible (which should have been the case at the time of diagnosis
anyway), as the two deaths mentioned were both in patients in whom neuroleptic
had been continued (15). The neuroleptic in these cases was a typical one, but the
caveat almost surely should extend to the newer, atypical antipsychotics also.
Second is that succinylcholine should be avoided as the paralyzing agent for ECT
if at all possible; this agent is known to predispose to abrupt hyperkalemia
(possibly the mechanism of death for the two cases mentioned), and conditions
favoring hyperkalemia are already extant in the situation (muscular injury from
rigidity and high body temperature; possible renal compromise from myoglobinuria and extracellular volume depletion; possibly a direct potassium-releasing
effect of ECT on skeletal muscle). The third follows from what has just been said:
serum potassium should be monitored very closely and great care should be taken
to ensure that extracellular volume has been repleted by adequate intravenous
supple-mentation (16).
Thinking of MC, NMS, and serotonin syndrome (SS) as variations on the same
theme, that of catatonia, makes it easier for me to remember how they present,
mainly as the same picture with some interesting differences: the excited,
prodromal phase may be missing and muscular rigidity earlier in NMS;
gastrointestinal distress, and maybe myoclonic seizures, more prominent in SS.
Seeing the one family makes it easier to pick up the distinctions among its
members. And, speaking of families, what a large number of conditions has been
reported to cause catatonia! Most of the reports are of the “benign” (simple,
retarded) form (BC), but I see no reason to presume that a condition capable of
causing BC could not also cause MC, as the latter may occur as an “advanced”
stage, or complication, of the former. I have gathered the conditions that I have
come across in the literature into two tables. The citations for these, in many
instances, are in the articles or books cited in the References section.

Table 1. Psychiatric Predispositions to Catatonia


mood disorders
mania or depression: ~ 50% of catatonias; 25-50% of all catatonics are manic



schizophrenia & other psychoses
~ 15% of catatonic adults; higher % in children







autism spectrum disorders
obsessive-compulsive disorder (at least the PANDAS form)
dissociative disorders/hypnosis
narcolepsy
periodic catatonia (a rare familial form, maybe autosomal dominant)

Jefferson Journal of Psychiatry, Volume 20, Number 1
© 2006 by the authors
On the Web: jdc.jefferson.edu/jeffjpsychiatry

ISSN 1935-0783

64

Table 2. Medical Predispositions to Catatonia
(Approximately 25% of catatonias have no psychiatric cause)

Neurological
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•

Von Economo’s encephalitis
HIV
Chagas disease (acute)
Lyme disease
Herpes simplex
GPI (CNS syphilis)
subacute sclerosing panencephalitis
acute disseminated encephalomyelitis
seizure disorder (esp in children), incl
postictal
postmalarial syndrome, w/ psychosis
head injury, including subdural hematoma
subarachnoid hemorrhage
basilar artery thrombosis
stroke (often cardioembolic)
Sheehan’s syndrome
paraneoplastic encephalopathy
periventricular diffuse pinealoma
tumor of septum pellucidum
subthalamic tumor, w/ hydrocephalus
alcoholic/Wernicke encephalopathy
multiple sclerosis
Parkinson’s disease
progressive supranuclear palsy
dementia with Lewy bodies
familial cerebellar-pontine atrophy
hereditary spinocerebellar degeneration
tuberous sclerosis
Creutzfeldt-Jacob disease
bilateral globus pallidus lesions
frontal, parietal, or thalamic lesions
arachnoid cyst

Systemic
•
•
•
•
•
•
•
•
•
•
•
•

SLE
FUO
TTP
Wilson’s disease
liver transplantation
hepatic encephalopathy
uremia
diabetic ketoacidosis
membranous GN
hyponatremia
burns
staphylococcal infection
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•
•
•
•
•
•
•
•
•
•

tetanus
tuberculosis
infectious mononucleosis
typhoid fever
PANDAS
vitamin B12 deficiency
hyperparathyroidism/hypoparathyroidism
pheochromocytoma
thyrotoxicosis
acute intermittent porphyria
Addison’s disease/Cushing’s disease

•
•
•
•
•
•

MEN, 1
hereditary coproporphyria
carcinoid tumor
homocystinuria
pellagra
Tay-Sach disease (adult form)

Toxic Effect of a Medication or Substance
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•

•
•
•
•
•
•
•
•
•

•

azithromycin
ciprofloxacin
bupropion
venlafaxine
clomipramine
methylphenidate
lithium
levetiracetam
neuroleptic (NMS)
serotonergic (SS)
corticosteroid, ACTH
fluorides
baclofen
disulfiram
cyclosporine
reserpine
metoclopramide
psilocybin
PCP
MDMA (ecstasy)
opiates
mescaline
illuminating gas
alcohol
aspirin (overdose)
strychnine
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Withdrawal from a Medication
•
•
•

lorazepam, other benzodiazepine
mixed sedative
carbamazapine

•
•
•

dopaminergic drugs
anticholinergic drugs
gabapentin

Hard to shake off vertigo from simply looking at these tables. Harder still to
imagine the disorder in the clinician’s mind, were there no unifying idea like
“catatonia” to bring them together under the one roof: otherwise we would be
trying to memorize, I suppose, the neuropsychiatric features one by one that each
was reputed to have caused. And we would have no idea at all how to proceed with
therapy. As it is, we can know this: the catatonic illness that each and every one of
these disorders can, on occasion, produce is treated in exactly the same way,
varying only according to its response to initial therapy, namely, to lorazepam! Of
course, with the exception of withholding typical neuroleptic in all catatonias until
the state is relieved, and withholding any antipsychotic, typical or atypical, in the
MC variant, it doesn’t hurt to treat the specific predisposition to the catatonic state,
too, whenever that is possible. Such is the value of a name, the right name. Which
doesn’t mean the future could not bring a better one, or reveal that we’d be better
off with more than one, and which names those should be.
Just why the two names, NMS and MC, fell apart and propagated separately is
unclear, to me anyway. It seems that some of the important writers about them in
decades past, Caroff and colleagues, and Fricchione and colleagues, took distinct
care to see that separate propagation did not occur. And yet it did. (Which is why
Dr. Fink has had to come to the rescue.) Perhaps psychiatry contains such variety it
has trouble keeping its language from splitting into dialects that soon fracture its
citizenry. Perhaps our textbook editors have under-appreciated the phenomenon of
catatonia (the topic surely gets short shrift in some), owing to having succumbed to
addictive properties in the format of the DSM-IV. The latter has an unstable
placement for catatonia (6), apparently out of loyalty, conscious or not, to the
outmoded conception that catatonia is mainly a schizophrenic condition. Perhaps
NMS, flirtatious as it is with the MH meme(s), has biological cachet for those who
are made anxious by the very subject of psychiatry, which is the mind.
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